Despite the observed resistance of certain cancer cell types in vitro (e.g. melanoma), IT injection of unconjugated Accum® could delay pre-established EL4 T-cell lymphoma growth when combined with ICIs; a therapeutic effect that seems to depend on dendritic cells as well as CD4 and CD8 lymphocytes [14]. This evidence concerns the gene CD8A and T-cell non-Hodgkin lymphoma.